Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs GoPro Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.34 (market cap $39.89B), while GoPro Inc trades at $0.72 (market cap $131.96M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 302.3× GoPro Inc's market cap. Which is the better fit depends on your goals.
| ALNY | GPRO | |
|---|---|---|
Market Cap | $39.89B | $131.96M |
Sector | Health | Technology |
52-Week High | $491.22 | $2.88 |
52-Week Low | $278.09 | $0.64 |
Enterprise Value | $38.15B | $179.91M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GoPro (GPRO) trades at $0.76, up 0.37% with neutral technical signals. The company faces severe financial distress with negative net income margins (-20.7%) and ROE (-236.05%), though valuation ratios appear low (P/E 4.56, P/S 0.2). Recent strategic review for potential sale and CEO's $20M financing provide near-term catalysts, but consecutive earnings misses and declining revenue ($652M in 2025) highlight operational challenges.
Outlook remains highly speculative with binary outcomes. The strategic sale process offers potential upside, but ongoing cash burn, negative equity, and competitive pressures present substantial downside risk. Analyst sentiment is mixed with 21% buy ratings, reflecting the company's precarious financial position and event-driven investment thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
